COST-EFFECTIVENESS OF BOCEPREVIR IN THE TREATMENT OF CHRONIC HEPATITIS C GENOTYPE 1 IN SWEDEN

被引：3
|
作者：
Chhatwal, J. [1 ]
Lundberg, J. [2 ]
Ferrante, S. [3 ]
El Khourhy, A. C. [4 ]
Oksanen, A. [5 ]
Elbasha, E. H. [3 ]
机构：
[1] Univ Pittsburgh, Dept Hlth Policy & Management, Pittsburgh, PA USA
[2] MSD, Sollentuna, Sweden
[3] Merck & Co Inc, Hlth Econ Stat, N Wales, PA USA
[4] Merck & Co Inc, Global Hlth Outcomes, West Point, PA USA
[5] Karolinska Univ Hosp, Dept Gastroenterol & Hepatol, Huddinge, Sweden
来源：
JOURNAL OF HEPATOLOGY | 2012年 / 56卷
关键词：
D O I：
10.1016/S0168-8278(12)61001-0
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
989
引用
收藏
页码：S386 / S387
页数：2
相关论文
共 50 条
  • [1] Cost-effectiveness of boceprevir or telaprevir for untreated patients with genotype 1 chronic hepatitis C
    Camma, Calogero
    Petta, Salvatore
    Enea, Marco
    Bruno, Raffaele
    Bronte, Fabrizio
    Capursi, Vincenza
    Cicchetti, Americo
    Colombo, Giorgio L.
    Di Marco, Vito
    Gasbarrini, Antonio
    Craxi, Antonio
    [J]. HEPATOLOGY, 2012, 56 (03) : 850 - 860
  • [2] Cost-effectiveness analysis of boceprevir for the treatment of chronic hepatitis C virus genotype 1 infection in Portugal
    Elbasha E.H.
    Chhatwal J.
    Ferrante S.A.
    El Khoury A.C.
    Laires P.A.
    [J]. Applied Health Economics and Health Policy, 2013, 11 (1) : 65 - 78
  • [3] COST-EFFECTIVENESS OF BOCEPREVIR THERAPY IN ADULT PATIENTS WITH CHRONIC HEPATITIS C (HCV) GENOTYPE 1
    Mernagh, P.
    Feng, J.
    Del Cuore, M.
    [J]. VALUE IN HEALTH, 2013, 16 (03) : A94 - A94
  • [4] Cost-effectiveness of boceprevir or telaprevir for previously treated patients with genotype 1 chronic hepatitis C
    Camma, Calogero
    Petta, Salvatore
    Cabibbo, Giuseppe
    Ruggeri, Matteo
    Enea, Marco
    Bruno, Raffaele
    Capursi, Vincenza
    Gasbarrini, Antonio
    Alberti, Alfredo
    Craxi, Antonio
    [J]. JOURNAL OF HEPATOLOGY, 2013, 59 (04) : 658 - 666
  • [5] The cost-effectiveness of boceprevir for hepatitis C
    Neoh, Chin Fen
    Kong, David C. M.
    [J]. EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2014, 14 (03) : 319 - 334
  • [6] COST-EFFECTIVENESS OF BOCEPREVIR ADD-ON TREATMENT OF HEPATITIS C VIRUS GENOTYPE 1 PATIENTS IN DENMARK
    Ehlers, L.
    Ferrante, S.
    Kristensen, M. H.
    Leutscher, P. D. C.
    Chhatwal, J.
    [J]. VALUE IN HEALTH, 2013, 16 (07) : A354 - A354
  • [7] Cost-Effectiveness Modeling Study of boceprevir for the treatment of patients with genotype 1 chronic hepatitis C virus infection in Hong Kong
    Ferrante, Shannon A.
    Yuen, Man-Fung
    Wong, Vincent W.
    Loo, Ching-Kong
    Chhatwal, Jagpreet
    Elbasha, Elamin
    [J]. HEPATOLOGY, 2013, 58 : 1136A - 1136A
  • [8] Cost-Effectiveness of Boceprevir in Patients Previously Treated for Chronic Hepatitis C Genotype 1 Infection in the United States
    Chhatwal, Jagpreet
    Ferrante, Shannon A.
    Brass, Cliff
    El Khoury, Antoine C.
    Burroughs, Margaret
    Bacon, Bruce
    Esteban-Mur, Rafael
    Elbasha, Elamin H.
    [J]. VALUE IN HEALTH, 2013, 16 (06) : 973 - 986
  • [9] COST-EFFECTIVENESS OF BOCEPREVIR BASED REGIMENS IN PREVIOUSLY UNTREATED ADULT SUBJECTS WITH CHRONIC HEPATITIS C GENOTYPE 1
    Ferrante, Shannon A.
    Chhatwal, Jagpreet
    Elbasha, Elamin
    Dasbach, Erik J.
    El Khoury, Antoine
    Poordad, F. Fred
    Bronowicki, Jean-Pierre
    Brass, Clifford A.
    [J]. HEPATOLOGY, 2011, 54 : 795A - 796A
  • [10] COST-EFFECTIVENESS OF BOCEPREVIR USE IN PATIENTS WITH CHRONIC HEPATITIS C GENOTYPE-1 WHO FAILED PRIOR TREATMENT WITH PEGINTERFERON/RIBAVIRIN
    Chhatwal, Jagpreet
    Ferrante, Shannon A.
    Dasbach, Erik J.
    El Khoury, Antoine
    Brass, Clifford A.
    Burroughs, Margaret
    Bacon, Bruce R.
    Esteban, Rafael
    Elbasha, Elamin
    [J]. HEPATOLOGY, 2011, 54 : 801A - 802A
12345